Overland Pharmaceuticals, backed by Hillhouse Capital, is building a fully integrated biopharma company with a mission to bring innovative medicines to underserved patients in Asia and around the world.
By leveraging our resources, global network, and local expertise across the biopharma ecosystem in Asia, Overland is establishing a portfolio of differentiated therapeutic candidates in a few carefully selected therapeutic areas.
Through formative R&D partnerships, Overland will move forward the development and commercialization of the most promising advances in medicine.
Through strategically engineered alliances, Overland focuses on innovative therapeutic programs and cutting-edge technology platforms to deliver maximum value to all stakeholders with the ultimate goal of serving patients around the world.
Overland’s flexible business approach and ability to architect differing partnership models (e.g. joint-venture, licensing, and equity investment deal structures), coupled with deep local expertise and a strong track record of achieving drug approvals in greater China, allows both Overland and its partners to benefit from each other’s respective strengths.
Therapeutic candidate programs across our portfolio are developed by our dedicated clinical and regulatory teams and other shared functional resources to achieve peak operational and capital efficiency.
We are committed to putting patients first and aim at fostering a culture of strong ethics and a high standard for quality.
We are launching a robust research and development engine of differentiated, novel therapeutics – all with the spirit and ambition of a nimble biotech.
Overland collaborates with innovative partners to jointly develop and strategically commercialize therapeutic programs for entry into Asia and expansion around the globe.
We accelerate the development of and access to promising new medicines for patients by sourcing the brightest talents and centralizing key operations.
Dr. Hua Mu serves as Co-founder, Interim CEO and CMO at Overland Pharmaceuticals, and Venture Partner, BioVenture at Hillhouse Capital.
Prior to Overland, Dr. Mu served as CSO and President of R&D and later CMO of Simcere Pharmaceutical Group and President of Simcere of America Inc. Before Simcere, he was SVP and Global Head of Product Development Service and Partnership at WuXi AppTec. Prior to WuXi, he was EVP and CMO at Hutchison MediPharma in China. He previously held Medical Director and Head of Medical Affairs positions at several global pharmaceutical companies in the US, including Roche, Abraxis Bioscience (Celgene/BMS), Biogen, and Genentech. With extensive experience in building and leading R&D organizations and international collaborations, Dr. Mu has a proven track record of successful development and approval of new drugs in China and around the globe. He participated in and led the development of more than 20 innovative drug candidates in multiple therapeutic areas, including three drugs approved in the US and global market, three in China, and 2 NDAs currently under priority review in China.
Dr. Mu conducted translational and clinical research at the University of California, San Francisco and at the University of Washington Medical School before joining industry in 1999. He received his PhD in Genetic Epidemiology from the University of California at Berkeley, under the mentorship of Dr. Mary-Claire King (discoverer of the breast cancer BRCA1 gene). Dr. Mu received his MD degree from West China University of Medical Sciences.
Ed Zhang, MBA, serves as Co-founder, COO and CBO at Overland Pharmaceuticals, and Venture Partner, BioVenture at Hillhouse Capital.
Prior to Overland, Ed was VP of Corporate Development at Boston Pharmaceuticals, representing a new biotech business model focused on translational clinical development. As part of its founding team, Ed led corporate development and strategic initiatives including establishing partnerships with leading global pharma and biotech companies. Prior to joining Boston Pharma, Ed headed Global Business Development for Sanofi’s Renal Strategic Unit and was Director of Commercial Operations and Strategic Development at Genzyme before acquisition by Sanofi. Ed started his career as a medicinal chemist at Pharmacia & Upjohn and now brings over 17 years of biopharma industrial experience to Overland.
Ed holds an MBA from Kellogg School of Management at Northwestern University, an MS in chemistry from Binghamton University, and a BS from Nanjing University.
Jie Li serves as SVP, Head of Regulatory Affairs at Overland Pharmaceuticals.
Prior to Overland, Jie held different Regulatory Affairs positions at Pfizer China since 1999 and led the department from 2010 until April 2020. In this role, she supported all facets of Pfizer China’s pharma business for registration strategy of all new products including small and large molecule drugs, and vaccines, in addition to license maintenance of approved products. She proactively partnered with industry associations and government agencies to introduce international best practices into China for NMPA’s regulatory system reform. In addition to Pfizer, she has experience working at other MNCs, such as SmithKline Beecham China, BMS China and Wyeth. She has also served as the Co-Chair of Regulatory Affairs Working Group in RDPAC (R&D Based Pharmaceutical Association Committee) in China. Jie holds over 25 years of regulatory affairs experience covering multiple therapeutic areas including cardiovascular and metabolic disease, neuroscience, oncology, infectious disease, inflammation & immunology, rare disease, endocrinology, and vaccine.
Jie received her MS from Peking Union Medical Colleague and BS in Medicine from Beijing University of Traditional Chinese Medicine.
Dr. Jie Chen serves as SVP, Head of Biometrics at Overland Pharmaceuticals.
Prior to Overland, Dr. Chen was a distinguished scientist in biostatistics at Merck Research Laboratories (US). He previously worked in China as Senior Global Group Head of Biostatistics at Novartis and as Senior Director and Head of Biometrics & Information Sciences at AstraZeneca and Merck Serono. He is also a member of the China Tripartite Coordination Committee, responsible for drafting and revising technical guidance for drug development in China. Dr. Chen holds 25 years of experience in biopharmaceutical R&D and has been invited to present at FDA/industry statistics workshops, EMA statistics symposia, and numerous other venues.
Dr. Chen received his PhD in Statistics from Temple University, Philadelphia, and his MD degree from Shanghai Medical College, Fudan University.
Kenneth Gao serves as VP of Alliance Management and Corporate Development at Overland Pharmaceuticals.
Prior to Overland, Kenneth most recently served as Senior Director of Corporate Development and Strategy as well as Head of China Operations at Assembly Biosciences. At Assembly Kenneth spearheaded establishment of Assembly China, led teams to execute strategic partnerships for assets in all development stages across the globe, and co-led multiple rounds of follow-on capital raising on Nasdaq. Before Assembly, he held various managerial positions in management consulting, transactions, and business operations at IMS Health, Eli Lilly, and Becton Dickinson. Kenneth also worked at Ennovance Capital, focused on mid-market private equity investments in the specialty chemical and pharmaceutical sectors.
Kenneth received an MBA in Health Sector Management from Duke University and a BS in Business Administration from State University of New York at Buffalo, NY.
Dr. Eric Hu serves as VP of Business Development at Overland Pharmaceuticals.
Prior to Overland, Dr. Hu was Senior Director of Business Development at Turning Point Therapeutics where he contributed to all aspects of strategic initiatives, deal sourcing, and diligence efforts. Before Turning Point Therapeutics, Dr. Hu spent over ten years at Gilead Sciences with increasing responsibilities from drug discovery to business development diligence. Dr. Hu is a coauthor of several high impact publications including Nature and Nature Medicine. Dr. Hu is also a key contributor and co-inventor of multiple clinical programs in antiviral, oncology, and inflammation including first-in-class long-acting HIV Capsid inhibitor Lenacapavir currently in multiple phase III clinical trials. Dr. Hu brings over 17 years of biopharmaceutical industry experience to Overland.
Dr. Hu received his Ph.D. in organic chemistry from University of California, Los Angeles, and BS from Beijing Normal University with honors.